Sareum Concludes Dosing in Phase 2-enabling Toxicology Program for Autoimmune Drug Candidate

05:21 AM EDT, 07/20/2026 (MT Newswires) -- Sareum Holdings (SAR.L) said Monday it completed dosing in the phase 2-enabling toxicology program for its autoimmune disease drug candidate SDC-1801, which is initially focusing on psoriasis. The British biotechnology company is using existing cash to evaluate the resulting data and to conduct chemistry, manufacturing, and controls and formulation development activities. The full phase 2-enabling regulatory package is on course for completion by the fourth quarter.